Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$27.35 USD
+1.34 (5.15%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $27.56 +0.21 (0.77%) 7:32 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 141 - 160 ( 287 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data Showcases Intellia?s Potential Safety and Efficacy Edge Over Competition
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Early Animal Proof of Concept Data For Gene Therapy Presented
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NTLA Flexing Its Gene Editing Platform at ESGCT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Enters Ocular Diseases Realm With Strategic Collaboration Agreement With SparingVision
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Collaboration with SparingVision to Develop Ocular Therapies
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NTLA''s New Collaboration Could Spare Vision
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Receives Authorization to Begin Phase 1/2 trial of NTLA-2002 for Treatment of Hereditary Angioedema (HAE)
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TCR Trial Posted on clinicaltrials.gov for AML
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Announces IND Acceptance For NTLA-5001, Its First CRISPR/Cas9 Engineered TCR T-Cell Therapy Candidate
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from Fireside Chat with Genome Editing Powerhouse Intellia; Poised to Round off Catalyst Rich Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Therapeutic Genome Editing Trailblazer Intellia Reports 2Q21 Earnings and Glad Tidings
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expecting a Full Knockout of TTR in the Next Round
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q21: More Data On Lead Program This Year. Target to $180
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T